To the scientific world, Moderna’s cancer vaccine’s results proved that a highly personalized, immune-targeting medication can work. To investors, it didn’t work well enough.


The company’s stock dropped after details of a study raised questions about how widely the treatment would be used.

No comments:

Post a Comment